218 related articles for article (PubMed ID: 29065825)
1. 2-Hydroxypropyl-β-cyclodextrins and the Blood-Brain Barrier: Considerations for Niemann-Pick Disease Type C1.
Calias P
Curr Pharm Des; 2017; 23(40):6231-6238. PubMed ID: 29065825
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
Ory DS; Ottinger EA; Farhat NY; King KA; Jiang X; Weissfeld L; Berry-Kravis E; Davidson CD; Bianconi S; Keener LA; Rao R; Soldatos A; Sidhu R; Walters KA; Xu X; Thurm A; Solomon B; Pavan WJ; Machielse BN; Kao M; Silber SA; McKew JC; Brewer CC; Vite CH; Walkley SU; Austin CP; Porter FD
Lancet; 2017 Oct; 390(10104):1758-1768. PubMed ID: 28803710
[TBL] [Abstract][Full Text] [Related]
3. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
[TBL] [Abstract][Full Text] [Related]
4. Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann-Pick C1 mutant cell via lysosome-associated membrane protein 1.
Singhal A; Szente L; Hildreth JEK; Song B
Cell Death Dis; 2018 Oct; 9(10):1019. PubMed ID: 30282967
[TBL] [Abstract][Full Text] [Related]
5. Characterization of hydroxypropyl-beta-cyclodextrins used in the treatment of Niemann-Pick Disease type C1.
Yergey AL; Blank PS; Cologna SM; Backlund PS; Porter FD; Darling AJ
PLoS One; 2017; 12(4):e0175478. PubMed ID: 28414792
[TBL] [Abstract][Full Text] [Related]
6. The susceptibility of cochlear outer hair cells to cyclodextrin is not related to their electromotile activity.
Zhou Y; Takahashi S; Homma K; Duan C; Zheng J; Cheatham MA; Zheng J
Acta Neuropathol Commun; 2018 Sep; 6(1):98. PubMed ID: 30249300
[TBL] [Abstract][Full Text] [Related]
7. Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin.
Cougnoux A; Clifford S; Salman A; Ng SL; Bertin J; Porter FD
Mol Genet Metab; 2018 Dec; 125(4):345-350. PubMed ID: 30392741
[TBL] [Abstract][Full Text] [Related]
8. 2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease.
Ward S; O'Donnell P; Fernandez S; Vite CH
Pediatr Res; 2010 Jul; 68(1):52-6. PubMed ID: 20357695
[TBL] [Abstract][Full Text] [Related]
9. Expanded access with intravenous hydroxypropyl-β-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis.
Hastings C; Vieira C; Liu B; Bascon C; Gao C; Wang RY; Casey A; Hrynkow S
Orphanet J Rare Dis; 2019 Oct; 14(1):228. PubMed ID: 31639011
[TBL] [Abstract][Full Text] [Related]
10. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease.
Vite CH; Bagel JH; Swain GP; Prociuk M; Sikora TU; Stein VM; O'Donnell P; Ruane T; Ward S; Crooks A; Li S; Mauldin E; Stellar S; De Meulder M; Kao ML; Ory DS; Davidson C; Vanier MT; Walkley SU
Sci Transl Med; 2015 Feb; 7(276):276ra26. PubMed ID: 25717099
[TBL] [Abstract][Full Text] [Related]
11. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in
Hoque S; Kondo Y; Sakata N; Yamada Y; Fukaura M; Higashi T; Motoyama K; Arima H; Higaki K; Hayashi A; Komiya T; Ishitsuka Y; Irie T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019132
[TBL] [Abstract][Full Text] [Related]
12. Modeling Niemann-Pick disease type C1 in zebrafish: a robust platform for
Tseng WC; Loeb HE; Pei W; Tsai-Morris CH; Xu L; Cluzeau CV; Wassif CA; Feldman B; Burgess SM; Pavan WJ; Porter FD
Dis Model Mech; 2018 Aug; 11(9):. PubMed ID: 30135069
[TBL] [Abstract][Full Text] [Related]
13. 2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease.
Davidson J; Molitor E; Moores S; Gale SE; Subramanian K; Jiang X; Sidhu R; Kell P; Zhang J; Fujiwara H; Davidson C; Helquist P; Melancon BJ; Grigalunas M; Liu G; Salahi F; Wiest O; Xu X; Porter FD; Pipalia NH; Cruz DL; Holson EB; Schaffer JE; Walkley SU; Maxfield FR; Ory DS
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1545-1561. PubMed ID: 31051283
[TBL] [Abstract][Full Text] [Related]
14. PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder.
Brown A; Patel S; Ward C; Lorenz A; Ortiz M; DuRoss A; Wieghardt F; Esch A; Otten EG; Heiser LM; Korolchuk VI; Sun C; Sarkar S; Sahay G
Sci Rep; 2016 Aug; 6():31750. PubMed ID: 27572704
[TBL] [Abstract][Full Text] [Related]
15. Investigating the Mechanism of Cyclodextrins in the Treatment of Niemann-Pick Disease Type C Using Crosslinked 2-Hydroxypropyl-β-cyclodextrin.
Carradori D; Chen H; Werner B; Shah AS; Leonardi C; Usuelli M; Mezzenga R; Platt F; Leroux JC
Small; 2020 Nov; 16(46):e2004735. PubMed ID: 33079457
[TBL] [Abstract][Full Text] [Related]
16. Decreased neural stem cell proliferation and olfaction in mouse models of Niemann-Pick C1 disease and the response to hydroxypropyl-β-cyclodextrin.
Dragotto J; Palladino G; Canterini S; Caporali P; Patil R; Fiorenza MT; Erickson RP
J Appl Genet; 2019 Nov; 60(3-4):357-365. PubMed ID: 31485950
[TBL] [Abstract][Full Text] [Related]
17. LC3 Immunostaining in the Inferior Olivary Nuclei of Cats With Niemann-Pick Disease Type C1 Is Associated With Patterned Purkinje Cell Loss.
Gurda BL; Bagel JH; Fisher SJ; Schultz ML; Lieberman AP; Hand P; Vite CH; Swain GP
J Neuropathol Exp Neurol; 2018 Mar; 77(3):229-245. PubMed ID: 29346563
[TBL] [Abstract][Full Text] [Related]
18. Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder.
Kulkarni A; Caporali P; Dolas A; Johny S; Goyal S; Dragotto J; Macone A; Jayaraman R; Fiorenza MT
Sci Rep; 2018 Jun; 8(1):9547. PubMed ID: 29934581
[TBL] [Abstract][Full Text] [Related]
19. Microglia activation in Niemann-Pick disease, type C1 is amendable to therapeutic intervention.
Cougnoux A; Drummond RA; Collar AL; Iben JR; Salman A; Westgarth H; Wassif CA; Cawley NX; Farhat NY; Ozato K; Lionakis MS; Porter FD
Hum Mol Genet; 2018 Jun; 27(12):2076-2089. PubMed ID: 29617956
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Treatment of Niemann-Pick Type C1 Disease With Intrathecal 2-Hydroxypropyl-β-Cyclodextrin.
Berry-Kravis E; Chin J; Hoffmann A; Winston A; Stoner R; LaGorio L; Friedmann K; Hernandez M; Ory DS; Porter FD; O'Keefe JA
Pediatr Neurol; 2018 Mar; 80():24-34. PubMed ID: 29429782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
